Now leaning towards short on MEDI. For one, Chiron is offering to up production of its flu vaccine. For another, there are various marketing and logistical problems associated with this launch (the current version may offer broader protection, but the distributor needs a freezer), as evidenced by the following post, whose author I am personally acquainted with.
Message 19579723
I think they've blown it for this year. Next season is another matter.
Aside to Jorj: Sorry, don't know diddly about VION. Doesn't look as though they have much cash. The recent payment by Chinese distributor will help a little, but the drug in question is only in Phase II. Kind of early to be lining up the vendors. I don't know the drug, and couldn't say what its chances might be. I don't think it's partnered with a cash rich pharma, so the trials are likely to be small, and the results heavily spun. Trade away with your charts, but my gut, operating with little information, says be careful in the longer haul.
Cheers, Tuck |
